Arcadia Biosciences, Inc. (RKDA)

NASDAQ: RKDA · Real-Time Price · USD
0.9556
-0.1144 (-10.69%)
At close: May 15, 2026, 4:00 PM EDT
0.9283
-0.0273 (-2.86%)
After-hours: May 15, 2026, 7:58 PM EDT
Market Cap1.97M -59.9%
Revenue (ttm)4.76M -9.5%
Net Income-9.32M
EPS-6.03
Shares Out 2.06M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume59,943
Open1.0400
Previous Close1.0700
Day's Range0.9100 - 1.0690
52-Week Range0.8900 - 6.7100
Beta0.52
AnalystsStrong Buy
Price Target12.00 (0.0%)
Earnings DateMay 14, 2026

About RKDA

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. Arcadia Biosciences, Inc. was incorporated in 2002 and is headquartered in Dallas, Texas.

IPO Date May 15, 2015
Employees 8
Stock Exchange NASDAQ
Ticker Symbol RKDA
Full Company Profile

Financial Performance

In 2025, Arcadia Biosciences's revenue was $4.86 million, a decrease of -3.71% compared to the previous year's $5.05 million. Losses were -$2.34 million, -66.77% less than in 2024.

Financial Statements

Analyst Summary

According to one analyst, the rating for RKDA stock is "Strong Buy" and the 12-month stock price target is $12.0.

Price Target
$12.0
( upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights

-- Zola ® volumes increase 18% year-over-year -- -- SG&A at lowest level in Arcadia's history -- DALLAS, May 14, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and mar...

3 days ago - GlobeNewsWire

Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights

-- Zola ® revenues increase 17% year-over-year -- -- Arcadia and Roosevelt Resources terminate proposed business combination --

7 weeks ago - GlobeNewsWire

Arcadia Biosciences files to sell 1.67M shares of common stock for holders

06:09 EST Arcadia Biosciences (RKDA) files to sell 1.67M shares of common stock for holders

3 months ago - TheFly

Arcadia announces exercise of preferred investment options for $2.1M in proceeds

Arcadia Biosciences (RKDA) has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares origin...

4 months ago - TheFly

Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds

DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) --  Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agre...

4 months ago - GlobeNewsWire

Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources

DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that on December 24, 2025, it received a ...

5 months ago - GlobeNewsWire

Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

-- Zola ® year-to-date revenues increase 26% year over year -- -- Arcadia gross profit margins exceed 30% for 11 th straight quarter -- -- Arcadia cash balance declines by only $257K to $1.1M -- DALLA...

6 months ago - GlobeNewsWire

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights

-- Arcadia revenues increase 11% year over year driven by 24% growth in Zola ® -- -- Arcadia receives 2.7 million shares of stock in ABVE --

9 months ago - GlobeNewsWire

Arcadia Biosciences Earnings Call Transcript: Q1 2025

Zola sales surged 90% year-over-year in Q1 2025, outpacing the coconut water category and driving a 22% revenue increase. The company exited its legacy agtech business, monetized IP, and reduced liabilities, while the Roosevelt Resources merger remains on track for completion by August.

1 year ago - Transcripts

Arcadia Biosciences reports Q1 revenue $1.2M vs $987k last yea

“The momentum we experienced in the second half of 2024 has continued into 2025, and we are very pleased with our first quarter results,” said T.J. Schaefer, CEO of Arcadia.

1 year ago - TheFly

Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

-- Revenues increase 22% year over year driven by 90% growth in Zola ® -- -- Arcadia sells patents for $750K and eliminates $1M in liabilities -- -- Roosevelt agreement amended to provide greater cert...

1 year ago - GlobeNewsWire

Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call

Arcadia Biosciences, Inc.® (Nasdaq: RKDA) will release its financial and business results for the first quarter of 2025 on May 8, 2025 at 2:00 p.m. ET.

1 year ago - GlobeNewsWire

Arcadia Biosciences Earnings Call Transcript: Q4 2024

2024 saw a strategic refocus on Zola coconut water, driving 46% sales growth and record distribution gains, while exiting underperforming brands and monetizing legacy assets. Gross margins remained strong, and the Roosevelt Resources transaction is expected to close by Q2 2025.

1 year ago - Transcripts

Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results f...

1 year ago - Business Wire

Arcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2024 Financial Results and Business Highlights Conference Call

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial ...

1 year ago - Business Wire

Arcadia Biosciences Transcript: M&A Announcement

Arcadia will issue shares to acquire Roosevelt, resulting in Roosevelt owning 90% of the combined entity. The deal enables Roosevelt to advance its large-scale CCUS and EOR project, with the company renamed Roosevelt Resources and led by Roosevelt’s management.

1 year ago - Transcripts

ARCADIA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Arcadia Biosciences, Inc. - RKDA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Arcadia Biosci...

1 year ago - Business Wire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Arcadia Biosciences, Inc.

NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Arcadia Biosciences, Inc. (NASDAQ: RKDA) and its board of directors concerning the propo...

1 year ago - PRNewsWire

Arcadia Biosciences to combine with Roosevelt Resources in an all-stock deal

Arcadia Biosciences (RKDA) and Roosevelt Resources announced that they have entered into a definitive securities exchange agreement which, when completed, will combine the two companies in an all-stoc...

1 year ago - TheFly

Arcadia Biosciences (RKDA) Enters Into Business Combination Agreement with Roosevelt Resources in All-Stock Transaction

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA) and Roosevelt Resources LP announced today that they have entered into a definitive securities exchange agreement which, when complet...

1 year ago - Business Wire

Arcadia Biosciences reports Q3 EPS ($1.18), consensus (81c)

Reports Q3 revenue $1.54M, consensus $1.4M.”We are extremely pleased with our third-quarter 2024 results, which represent the progress we have made in transforming Arcadia’s business as well as our ab...

1 year ago - TheFly

Arcadia Biosciences Earnings Call Transcript: Q3 2024

Q3 2024 saw 18% revenue growth, led by a 55% increase in Zola sales and major distribution gains. Cash burn hit historic lows, and Zola outpaced the coconut water category, with new product launches planned for next year.

1 year ago - Transcripts

Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2024 Financial Results and Business Highlights

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results f...

1 year ago - Business Wire

Arcadia Biosciences (RKDA) Announces Date of Third Quarter 2024 Financial Results and Business Highlights Conference Call

DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial ...

1 year ago - Business Wire

Arcadia Biosciences Earnings Call Transcript: Q2 2024

Q2 2024 marked a strategic shift, with wheat IP monetization and GoodWheat exit fueling cost savings and a focus on Zola Coconut Water, which saw 42% sales growth. Revenues are expected to match 2023, with gross margins in the low 40s and cash burn halved.

1 year ago - Transcripts